60 citations
,
October 2020 in “Nature Communications” AP-1 and TGFß work together to drive resistance in basal cell carcinoma, suggesting new treatment options.
7 citations
,
October 2011 in “BMC Cancer” Overexpression of HDGF in melanocytes does not cause cancer.
67 citations
,
April 2018 in “JAMA Dermatology” Hair loss from hormone therapy in breast cancer patients can be improved with minoxidil treatment.
Upadacitinib effectively treated a patient with multiple inflammatory conditions.
More research is needed to confirm the potential of various treatments, including Helichrysum plicatum, vitamins, bromelain, personalized medications, hydrogels, and bacteriophage therapy.
December 2020 in “International journal of medical science and clinical invention” Rapunzel syndrome can show vague symptoms and needs long-term psychiatric care to prevent recurrence.
September 2009 in “European Urology Supplements” IGRT resulted in lower acute toxicity for stage III prostate cancer patients.
June 2023 in “British Journal of Dermatology” Coinheritance of BRCA2 and CYLD genes may lead to new treatment options for certain cancers.
39 citations
,
March 2009 in “Dermatology Online Journal” Erlotinib can cause persistent excessive hair growth.
6 citations
,
December 2015 in “JAMA” The woman's high testosterone levels indicated PCOS, leading to treatment that improved her symptoms.
19 citations
,
June 2001 in “Annals of Internal Medicine” Tamoxifen can cause total hair loss but its benefits outweigh this side effect.
15 citations
,
May 2021 in “Climacteric” Postmenopausal hyperandrogenism involves excess male hormones causing symptoms like hair growth and acne, and requires ruling out tumors and other disorders.
8 citations
,
June 2014 in “PubMed” Men are more likely to have larger basal cell carcinomas and squamous cell carcinomas, while women have more superficial basal cell carcinomas and tumors on their legs and central face.
224 citations
,
February 2013 in “The Journal of clinical investigation/The journal of clinical investigation” ERG increases SOX9, promoting prostate cancer growth and invasion.
15 citations
,
May 1997 in “Annals of Internal Medicine” Tamoxifen caused hair loss in a 52-year-old woman.
March 2010 in “European Journal of Cancer Supplements”
130 citations
,
June 2003 in “Journal of Investigative Dermatology Symposium Proceedings” Estrogen Receptor ß (ERß) is the main hormone controller in human skin and hair follicles, not Estrogen Receptor α (ERα) or the Androgen Receptor (AR).
November 2022 in “American Journal of Clinical Pathology” TURP specimens should be checked for various tumors, not just common prostate issues.
May 2021 in “Journal of the Endocrine Society” A woman developed male characteristics after using unregulated hormone therapy.
39 citations
,
September 2007 in “BMC developmental biology” Neuregulin3 affects cell development in the skin and mammary glands.
December 1997 in “Journal of The European Academy of Dermatology and Venereology” Most women with excessive hair growth have a hormonal cause.
3 citations
,
April 2020 in “PubMed” Combining DEB-BACE with chemotherapy is more effective and has fewer side effects than chemotherapy alone for treating unresectable lung squamous cell carcinoma.
The document concludes that the development of certain tumors is influenced by genetic background and that a specific gene modification can lead to tumor regression and reduced growth.
October 2021 in “International journal of basic and clinical pharmacology” Excessive eyelash growth from erlotinib may indicate positive tumor response and help treat madarosis.
12 citations
,
July 2019 in “Veterinary Dermatology” Nestin-expressing progenitor cells become outer root sheath keratinocytes.
July 2017 in “Cancer Research” Krt15+ cells in mice can resist radiation, regenerate tissue, and start tumors, suggesting new cancer treatment targets.
68 citations
,
November 2011 in “The American journal of pathology” Abnormal Hedgehog signaling in blood cancers may help tumors grow and resist chemotherapy, suggesting potential for targeted treatments.
July 2023 in “Journal of the ASEAN Federation of Endocrine Societies” GnRH agonist effectively diagnoses and treats postmenopausal hyperandrogenism from ovarian sources.
159 citations
,
October 1986 in “The Histochemical Journal”
7 citations
,
December 2014 in “Australasian journal of dermatology” Insulin resistance is not more common in idiopathic hirsutism patients than in healthy individuals.